Tirzepatide (LY3298176), a dual GIP and GLP-1 Ra, was discovered by engineering GLP-1 activity into the GIP sequence, which has the potential to be one of the most effective therapeutics for treating T2D with respect to both glycemia and body weight control as the disease progresses [11]. Here, GLP1R is linked to type 2 diabetes mellitus.